What is Wedbush’s Estimate for KROS Q4 Earnings?

Keros Therapeutics, Inc. (NASDAQ:KROS) – Investment analysts at Wedbush issued their Q4 2025 EPS estimates for Keros Therapeutics in a report issued on Monday, November 4th. Wedbush analyst Y. Zhong expects that the company will earn ($1.27) per share for the quarter. Wedbush has a “Strong-Buy” rating on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.90) per share.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The firm had revenue of $0.04 million for the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. During the same period in the previous year, the business posted ($1.27) earnings per share.

Other equities analysts have also issued research reports about the company. Bank of America decreased their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Guggenheim initiated coverage on Keros Therapeutics in a research report on Monday, September 23rd. They issued a “buy” rating and a $96.00 target price on the stock. Scotiabank assumed coverage on shares of Keros Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price for the company. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research note on Tuesday. They issued a “buy” rating on the stock. Finally, Cantor Fitzgerald started coverage on shares of Keros Therapeutics in a research note on Thursday, October 24th. They issued an “overweight” rating for the company. Eleven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Keros Therapeutics has an average rating of “Buy” and an average price target of $89.11.

Keros Therapeutics Stock Performance

Shares of KROS opened at $66.45 on Wednesday. The firm has a 50 day simple moving average of $56.87 and a two-hundred day simple moving average of $51.89. Keros Therapeutics has a one year low of $27.31 and a one year high of $73.00.

Institutional Investors Weigh In On Keros Therapeutics

Large investors have recently modified their holdings of the company. KBC Group NV lifted its holdings in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the period. Values First Advisors Inc. bought a new stake in Keros Therapeutics in the third quarter worth approximately $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Keros Therapeutics in the second quarter valued at approximately $128,000. Finally, Ameritas Investment Partners Inc. boosted its holdings in shares of Keros Therapeutics by 14.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after buying an additional 324 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Carl L. Gordon sold 250,000 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 22.90% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.